Abstracts tagged "prevention"

Abstract Number: 2038 • ACR Convergence 2023
Impact of COVID-19 Pandemic on Preventative Health Screenings in Rheumatology Outpatients
Minerva Nong¹, Medha Barbhaiya², Jonah Levine³, Vivian Bykerk⁴, Rachel Heise⁵ and Lisa Mandl², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Department of Population Health Sciences, Weill Cornell Medicine, New York, NY
Background/Purpose: The COVID-19 pandemic created significant barriers to accessing recommended preventative health screening. Patients already managing a chronic disease, particularly those using immunosuppressive medications, may…
Abstract Number: 0835 • ACR Convergence 2023
Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial
Andrew Cope¹, Marianna Jasenecova², Joana Vasconcelos³, Andrew Filer⁴, Karim Raza⁵, Sumera Qureshi², Maria Antonietta D'Agostino⁶, Iain McInnes⁷, John Isaacs⁸, Arthur Pratt⁹, Benjamin A Fisher⁴, Christopher Buckley¹⁰, Paul Emery¹¹, Pauline Ho¹², Maya Buch¹³, Coziana Ciurtin¹⁴, René Toes¹⁵, Thomas Huizinga¹⁵, Dirkjan van Schaardenburg¹⁶, Caroline Caroline¹⁷ and Toby Prevost³, ¹King's College London, London, United Kingdom, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's College London, London, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁹Translational & Clinical Research Institute, University of Newcastle, Newcastle, United Kingdom, ¹⁰University of Oxford, Oxford, United Kingdom, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹³University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ¹⁴Centre for Rheumatology Research, University College London, London, United Kingdom, ¹⁵Leiden University Medical Center, Leiden, Netherlands, ¹⁶Reade, Amsterdam, Netherlands, ¹⁷King's Clinical Trials Unit, King's College London, London, United Kingdom
Background/Purpose: The definition of higher risk states for rheumatoid arthritis (RA) has been refined in more recent years through inclusion of serum autoantibodies and symptom…
Abstract Number: 2055 • ACR Convergence 2023
A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study
Racheal Githumbi¹, Susan Kuhn¹, Carla Osiowy², Jennifer DeBruyn¹, Marvin Fritzler¹, Nicole Johnson¹, Otto G Vanderkooi¹ and Heinrike Schmeling¹, ¹University of Calgary, Calgary, AB, Canada, ²National Microbiology Laboratory, Public Health Agency of Canada, Winnepig, MB, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) and Crohn's disease (CD) are now controlled using immunosuppressive medications. However, disease control comes at the risk of increased infection.…
Abstract Number: 0858 • ACR Convergence 2023
Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis
Benjamin Terrier¹, Gregory Pugnet², Marie-Emmanuelle Sirieix³, Thomas Quemeneur⁴, Xavier Puéchal⁵, Francois Maurier⁶, Antoine Néel⁷, YGAL BENHAMOU⁸, Bernard Bonnotte⁹, Jean Schmidt¹⁰, Adrien Michon³, Antoine Baudet¹¹, Pierre Charles¹², Fleur Cohen¹³, Claire De Moreuil¹⁴, Emanuelle Dernis¹⁵, Pauline Belenotti¹⁶, Marc Ruivard¹⁷, Olivier Aumaitre¹⁸, Olivier Fain¹⁹, Raphaele Seror²⁰, Cécile-Audrey Durel²¹, Noémie Jourde-Chiche²², Estibaliz Lazaro²³, Gilles Chironi²⁴, Guillaume Armengol²⁵, Jeremy Bellien²⁵, Philippe Ravaud²⁶, Gabriel Baron²⁶ and Loic Guillevin²⁷, ¹Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³HEGP, Paris, France, ⁴CH Valenciennes, Valenciennes, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁶Hôpitaux privés de Metz, Vaux / Frankreich, France, ⁷CHU Nantes, Nantes, France, ⁸rouen university hospital, Rouen, France, ⁹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹⁰CHU Amiens, Amiens, France, ¹¹CH Annecy, Annecy, France, ¹²Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ¹³Sorbonne Université, Paris, France, ¹⁴CHU de Brest, Brest, France, ¹⁵CH Le Mans, Le Mans, France, ¹⁶CHU Marseille, Marseille, France, ¹⁷CHU Clermont Ferrand, Clermont Ferrand, France, ¹⁸CHU Saint Antoine, Paris, France, ¹⁹Hopital SAINT ANTOINE APHP, Paris, France, ²⁰University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ²¹CHU Lyon, Lyon, France, ²²AP-HM, Marseille, France, ²³Bordeaux Hospital University, Pessac, France, ²⁴Monaco, Monaco, Monaco, ²⁵CHU Rouen, Rouen, France, ²⁶Paris Cité University, Paris, France, ²⁷University Paris Descartes, Paris, France
Background/Purpose: Despite more effective therapeutic strategies in ANCA-associated vasculitis (AAV), there is still a significant risk of morbidity and mortality, mainly due to infection, and…
Abstract Number: 2132 • ACR Convergence 2023
Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates
Claire Daien¹, Vera Georgescu², Guillaume Decarriere³, Gael Mouterde³, Cedric Lukas⁴, Gregoire Mercier² and JACQUES MOREL⁵, ¹University Hospital, Montpellier, France, ²Department of Medical Information, Montpellier, France, ³Rheumatology, Montpellier, France, ⁴CHU Montpellier, Montpellier, France, ⁵Protocole thérapeutique immuno-rhumatologie, Montpellier, France
Background/Purpose: Systematic screening for multimorbidities has been carried out since 2014 at Montpellier University Hospital in patients with chronic inflammatory rheumatism (IRD). The aim of…
Abstract Number: 0938 • ACR Convergence 2023
Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum
Sunhwa Kim¹, Thierry Sornasse², Vishal Kakkar³, Rebecca Ross⁴, Yingtao Bi⁵, Hengcheng Hu², Lisa Hazelwood², Lauren Reinke-Breen⁶, jozsef karman⁷, Chris Butler², Jennifer Van Camp² and Francesco Del Galdo⁸, ¹AbbVie, Inc., South San Francisco, CA, ²AbbVie, Inc., North Chicago, IL, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁵AbbVie, Inc., Worcester, MA, ⁶AbbVie, Inc., Vernon Hills, IL, ⁷AbbVie, Inc., San Francisco, CA, ⁸University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organs asynchronously, leading to highly variable fibrotic damage and consequent increased morbidity and mortality.…
Abstract Number: 2283 • ACR Convergence 2023
Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness
Arthur Mageau¹, Julia Simard², Elisabet Svenungsson³ and Elizabeth Arkema⁴, ¹Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden / Internal Medicine Unit, Hopital Bichat, Paris, France, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Real-world data assessing the effectiveness of the anti-SARS-CoV2 vaccination in patients living with systemic lupus erythematosus (SLE) are currently lacking. We aimed to describe…
Abstract Number: 1087 • ACR Convergence 2023
Characterizing Herpes Zoster Vaccination Patterns in Rheumatoid Arthritis Patients in a Tertiary Care Clinic: A Quality Improvement Approach
Sara Faghihi-Kashani, Arooj Babar and Janice Lin, Stanford University, Palo Alto, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) face an increased risk of herpes zoster (HZ) infection, notably those on immunosuppressive therapy. Herpes zoster infection is associated…
Abstract Number: 2285 • ACR Convergence 2023
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update
J. Patricia Dhar¹, Hannah Forsythe², Louis Saravolatz¹ and Susanna Szpunar³, ¹Ascension St. John Hospital and Wayne State University School of Medicine, Detroit, MI, ²Michigan Department of Human and Health Services, Lansing, MI, ³Ascension St. John Hospital, Detroit, MI
Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…
Abstract Number: 1089 • ACR Convergence 2023
Improving Recombinant Zoster Vaccination Rates Among Immunosuppressed Veterans in an Academic Rheumatology Clinic
Nagendra Pokala¹, Benjamin Gardner², Avni Amratia¹, Daniel Emesiani³, Jiby Mathew⁴, Rashmi Arora⁵, Una Makris⁶ and Swathi Reddy⁷, ¹Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, ³Baylor Scott and White Medical Center McKinney, Dallas, TX, ⁴VA North Texas Healthcare System, Dallas, TX, ⁵Department of Internal Medicine, UT Southwestern Medical Center; VA North Texas Healthcare System, Dallas, TX, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁷UT Southwestern Medical Center / Dallas VA Medical Center, Colleyville, TX
Background/Purpose: Due in part to immunosuppressant medications, patients with rheumatic diseases not only carry a higher risk of herpes zoster reactivation but also worse outcomes.…
Abstract Number: 2490 • ACR Convergence 2023
Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial
Junna Ye¹, Yijun You², Zhuochao Zhou², Jingyi Wu², Fan wang² and Chengde Yang², ¹Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Previous clinical trials of mycophenolate mofetil (MMF) in SLE were mainly focused on lupus nephritis (LN) (patients have been diagnosed with LN). In the…
Abstract Number: 055 • 2023 Pediatric Rheumatology Symposium
COVID-19 Vaccination in Children with Rheumatic Diseases: Results of a CARRA-wide Survey
Beth Rutstein¹, Merav Heshin Bekenstein², Maria Schletzbaum³, Nora Singer⁴, Rebecca Sadun⁵, Melanie Kohlheim⁶, Vincent Del Gaizo⁷, Kelly Wise⁸, Melica Nikahd⁹, Guy Brock⁹, Monica Ardura⁸, Vidya Sivaraman¹⁰ and For the CARRA Investigators¹¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Medical College of Wisconsin, Milwaukee, WI, ⁴Metro Health, Cleveland, OH, ⁵Duke University, Durham, NC, ⁶None, Columbus, OH, ⁷CARRA, Washington, DC, ⁸Nationwide Children's Hospital, Columbus, OH, ⁹The Ohio State University, Columbus, OH, ¹⁰Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ¹¹Duke University Medical Center, Durham, NC
Background/Purpose: Children receiving immunosuppressive therapies (IST) have a higher risk of hospitalization from COVID-19. COVID-19 vaccines significantly reduce the likelihood of severe disease or death.…
Abstract Number: L08 • ACR Convergence 2022
Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Christopher Podgorski¹ and Deborah Parks², ¹BJC/Washington University Consortium, St. Louis, MO, ²Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Treatment with Tixagevimab/Cilgavimab 150/150 mg was authorized by the FDA on 12/8/21 under an Emergency Use Authorization as pre-exposure prophylaxis against COVID-19 infection. The…
Abstract Number: L16 • ACR Convergence 2022
Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
Benjamin Terrier¹, Laura Richert², Grégory Pugnet³, Olivier Aumaitre⁴, Olivier Moranne⁵, Elisabeth Diot⁶, Alexandre Karras⁷, Fabrice Bonnet⁸, Claire De Moreuil⁹, Eric Hachulla¹⁰, Thomas Le Gallou¹¹, Céline Lebas¹⁰, Francois Maurier¹², Cédric Rafat⁷, Maxime Samson¹³, Jean-Francois Augusto¹⁴, Grégoire Couvrat-Devergne¹⁵, Cécile Janssen¹⁶, Thierry Martin¹⁷, Thomas Quemeneur¹⁸, Pierre-Louis Caron¹⁹, Cécile-Audrey Durel²⁰, Khalil El Karoui⁷, Aurélie Grados²¹, Mathieu Puyade²², Virginie Rieu⁴, Yurdagul Uzunhan²³, Jean-Francois Viallard⁸, Xavier Puéchal⁷, Loic Guillevin⁷, Noémie Huchet⁸, Hendy Abdoul⁷, Carine Bellera⁸, Frédéric Batteux⁷ and Odile Launay⁷, ¹Cochin Hospital, Paris, France, ²EUCLID, Bordeaux, France, ³CHU, Toulouse, France, ⁴CHU, Clermont-Ferrand, France, ⁵CHU, Nimes, France, ⁶CHU, Tours, France, ⁷CHU, Paris, France, ⁸CHU, Bordeaux, France, ⁹CHU, Brest, France, ¹⁰CHU, Lille, France, ¹¹CHU, Rennes, France, ¹²CH, Metz, France, ¹³CHU, Dijon, France, ¹⁴CHU, Angers, France, ¹⁵CH, La Roche sur Yon, France, ¹⁶CH, Annecy, France, ¹⁷CHU, Strasbourg, France, ¹⁸CH, Valenciennes, France, ¹⁹CHU, Grenoble, France, ²⁰CHU, Lyon, France, ²¹CH, Niot, France, ²²CHU, Poitiers, France, ²³CHU, Bobigny, France
Background/Purpose: Patients receiving glucocorticoids plus rituximab (RTX) show an increased risk of infection, especially invasive pneumococcal infections. Vaccine responses to influenza, Streptococcus pneumoniae and SARS-CoV-2…
Abstract Number: 0616 • ACR Convergence 2022
Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes
Liam O'Neil¹, XIAOBO MENG¹, Caitin McFadyen¹, Marvin Fritzler² and Hani El-Gabalawy¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Calgary, Calgary, AB, Canada
Background/Purpose: The detection of anti-citrullinated protein antibodies (ACPA) is associated with increased risk for development of future Rheumatoid Arthritis (RA). The biological events that underpin…

« Previous Page
1
…
3
4
5
6
7
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].